Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31996411,sodium excretion,Dietary sodium restriction reduced sodium excretion from 160 to 64 mmol per day.,A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996411/),[mM] / [d],160,839,DB00594,Amiloride
,7917906,half-life,"The pharmacokinetics of HMA in mice was studied by using high-performance liquid chromatography: after intraperitoneal injection of 20 micrograms g-1, the plasma level of HMA peaked at 8 microM after about 15 min and decreased to 1 microM at 120 min; the half-life was 35 min.","Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917906/),min,35,3609,DB00594,Amiloride
,7917906,surviving fraction,"Nigericin and HMA, at doses of 1.25 micrograms g-1 and 10 micrograms g-1 respectively, failed to cause significant cell killing in the EMT-6 murine tumour, but the surviving fraction was reduced to approximately 0.004 when hydralazine was administered with nigericin and HMA.","Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917906/),,0.004,3610,DB00594,Amiloride
,30032652,% transmittance,"The experimental values observed for dependent variables such as hydrodynamic diameter (nm), % transmittance and % cumulative drug release were found to be 89.36 ± 11.18 nm, 99.23 ± 0.84% and 80.36 ± 5.48%, respectively.",Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032652/),%,99.23,10495,DB00594,Amiloride
,30032652,% cumulative drug release,"The experimental values observed for dependent variables such as hydrodynamic diameter (nm), % transmittance and % cumulative drug release were found to be 89.36 ± 11.18 nm, 99.23 ± 0.84% and 80.36 ± 5.48%, respectively.",Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032652/),%,80.36,10496,DB00594,Amiloride
,30032652,polydispersity index,"Results showed; a spherical shape (transmission electron microscopy and scanning electron microscopy - assisted morphological characterization), polydispersity index (0.231 ± 0.018), zeta potential (-9.83 ± 0.12 mV), refractive index (1.38 ± 0.042), viscosity (41 ± 5 cp), pH (6.4 ± 0.18) and drug content of 98.28 ± 0.29%, for optimized Amiloride-loaded-Nanoemulsion (Amilo-NE).",Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032652/),,0.231,10497,DB00594,Amiloride
,30032652,zeta potential,"Results showed; a spherical shape (transmission electron microscopy and scanning electron microscopy - assisted morphological characterization), polydispersity index (0.231 ± 0.018), zeta potential (-9.83 ± 0.12 mV), refractive index (1.38 ± 0.042), viscosity (41 ± 5 cp), pH (6.4 ± 0.18) and drug content of 98.28 ± 0.29%, for optimized Amiloride-loaded-Nanoemulsion (Amilo-NE).",Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032652/),mv,-,10498,DB00594,Amiloride
,30032652,zeta potential,"Results showed; a spherical shape (transmission electron microscopy and scanning electron microscopy - assisted morphological characterization), polydispersity index (0.231 ± 0.018), zeta potential (-9.83 ± 0.12 mV), refractive index (1.38 ± 0.042), viscosity (41 ± 5 cp), pH (6.4 ± 0.18) and drug content of 98.28 ± 0.29%, for optimized Amiloride-loaded-Nanoemulsion (Amilo-NE).",Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032652/),mv,9.83,10499,DB00594,Amiloride
,30032652,refractive index,"Results showed; a spherical shape (transmission electron microscopy and scanning electron microscopy - assisted morphological characterization), polydispersity index (0.231 ± 0.018), zeta potential (-9.83 ± 0.12 mV), refractive index (1.38 ± 0.042), viscosity (41 ± 5 cp), pH (6.4 ± 0.18) and drug content of 98.28 ± 0.29%, for optimized Amiloride-loaded-Nanoemulsion (Amilo-NE).",Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032652/),,1.38,10500,DB00594,Amiloride
,30032652,viscosity,"Results showed; a spherical shape (transmission electron microscopy and scanning electron microscopy - assisted morphological characterization), polydispersity index (0.231 ± 0.018), zeta potential (-9.83 ± 0.12 mV), refractive index (1.38 ± 0.042), viscosity (41 ± 5 cp), pH (6.4 ± 0.18) and drug content of 98.28 ± 0.29%, for optimized Amiloride-loaded-Nanoemulsion (Amilo-NE).",Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032652/),cp,41,10501,DB00594,Amiloride
,24272694,λex,"The eluted drug is further resolved from endogenous interferences on a Waters' C-18 µBondapak analytical column with a mobile phase consisting of methanol:sodium perchlorate (0.1 M, pH 4.0) 40:60 v/v and fluorescence detection (λex = 368 nm, λem = 417 nm).",Amiloride: biological fluid analysis by reverse-phase HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24272694/),nm,368,12667,DB00594,Amiloride
,24272694,λem,"The eluted drug is further resolved from endogenous interferences on a Waters' C-18 µBondapak analytical column with a mobile phase consisting of methanol:sodium perchlorate (0.1 M, pH 4.0) 40:60 v/v and fluorescence detection (λex = 368 nm, λem = 417 nm).",Amiloride: biological fluid analysis by reverse-phase HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24272694/),nm,417,12668,DB00594,Amiloride
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,3.5,42337,DB00594,Amiloride
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,29,42338,DB00594,Amiloride
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,29,42339,DB00594,Amiloride
,16702900,clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],160,42340,DB00594,Amiloride
,16702900,renal clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],20,42341,DB00594,Amiloride
,16702900,renal clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],15,42342,DB00594,Amiloride
exceed,9210443,extraction recoveries,"The extraction recoveries, depending on concentration, exceed 80% for furosemide and 74% for amiloride.",Determination and pharmacokinetics of a furosemide-amiloride drug combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210443/),%,80,62308,DB00594,Amiloride
,9210443,extraction recoveries,"The extraction recoveries, depending on concentration, exceed 80% for furosemide and 74% for amiloride.",Determination and pharmacokinetics of a furosemide-amiloride drug combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210443/),%,74,62309,DB00594,Amiloride
,9085317,maximum peak concentration (Cmax),"After oral dosing, the mean +/- SD maximum peak concentration (Cmax) was 20.6 +/- 10.0 ng/ml at 3.2 +/- 1.2 hours in adults and 21.7 +/- 4.88 at 2.9 +/- 0.6 hours in the adolescents.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[ng] / [ml],20.6,64638,DB00594,Amiloride
,9085317,maximum peak concentration (Cmax),"After oral dosing, the mean +/- SD maximum peak concentration (Cmax) was 20.6 +/- 10.0 ng/ml at 3.2 +/- 1.2 hours in adults and 21.7 +/- 4.88 at 2.9 +/- 0.6 hours in the adolescents.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[ng] / [ml],21.7,64639,DB00594,Amiloride
,9085317,area under the concentration-time curve (AUC) from time zero to infinity hours,"Mean area under the concentration-time curve (AUC) from time zero to infinity hours was 275 +/- 115 and 254 +/- 60 ng.hr/ml in the adult and adolescent groups; half-life was 16.0 +/- 0.7 and 13.4 +/- 1.4 hours, respectively.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[h·ng] / [ml],275,64640,DB00594,Amiloride
,9085317,area under the concentration-time curve (AUC) from time zero to infinity hours,"Mean area under the concentration-time curve (AUC) from time zero to infinity hours was 275 +/- 115 and 254 +/- 60 ng.hr/ml in the adult and adolescent groups; half-life was 16.0 +/- 0.7 and 13.4 +/- 1.4 hours, respectively.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[h·ng] / [ml],254,64641,DB00594,Amiloride
,9085317,half-life,"Mean area under the concentration-time curve (AUC) from time zero to infinity hours was 275 +/- 115 and 254 +/- 60 ng.hr/ml in the adult and adolescent groups; half-life was 16.0 +/- 0.7 and 13.4 +/- 1.4 hours, respectively.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),h,16.0,64642,DB00594,Amiloride
,9085317,half-life,"Mean area under the concentration-time curve (AUC) from time zero to infinity hours was 275 +/- 115 and 254 +/- 60 ng.hr/ml in the adult and adolescent groups; half-life was 16.0 +/- 0.7 and 13.4 +/- 1.4 hours, respectively.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),h,13.4,64643,DB00594,Amiloride
,9085317,Cmax1,"After nebulization, 14 of 19 subjects exhibited two concentration peaks (Cmax1 and Cmax2) with mean values of 1.57 +/- 1.67 ng/ml at 0.5 +/- 0.2 hours and 1.37 +/- 1.21 ng/ml at 4.0 +/- 1.0 hours for adults, and 1.49 +/- 0.99 ng/ml at 0.5 +/- 0.1 hours and 1.52 +/- 0.81 ng/ml at 3.3 +/- 0.5 hours for adolescents.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[ng] / [ml],1.57,64644,DB00594,Amiloride
,9085317,Cmax1,"After nebulization, 14 of 19 subjects exhibited two concentration peaks (Cmax1 and Cmax2) with mean values of 1.57 +/- 1.67 ng/ml at 0.5 +/- 0.2 hours and 1.37 +/- 1.21 ng/ml at 4.0 +/- 1.0 hours for adults, and 1.49 +/- 0.99 ng/ml at 0.5 +/- 0.1 hours and 1.52 +/- 0.81 ng/ml at 3.3 +/- 0.5 hours for adolescents.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[ng] / [ml],1.49,64645,DB00594,Amiloride
,9085317,Cmax2,"After nebulization, 14 of 19 subjects exhibited two concentration peaks (Cmax1 and Cmax2) with mean values of 1.57 +/- 1.67 ng/ml at 0.5 +/- 0.2 hours and 1.37 +/- 1.21 ng/ml at 4.0 +/- 1.0 hours for adults, and 1.49 +/- 0.99 ng/ml at 0.5 +/- 0.1 hours and 1.52 +/- 0.81 ng/ml at 3.3 +/- 0.5 hours for adolescents.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[ng] / [ml],1.37,64646,DB00594,Amiloride
,9085317,Cmax2,"After nebulization, 14 of 19 subjects exhibited two concentration peaks (Cmax1 and Cmax2) with mean values of 1.57 +/- 1.67 ng/ml at 0.5 +/- 0.2 hours and 1.37 +/- 1.21 ng/ml at 4.0 +/- 1.0 hours for adults, and 1.49 +/- 0.99 ng/ml at 0.5 +/- 0.1 hours and 1.52 +/- 0.81 ng/ml at 3.3 +/- 0.5 hours for adolescents.",Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[ng] / [ml],1.52,64647,DB00594,Amiloride
,9085317,AUC from time zero to the last measurable plasma amiloride concentration,Mean +/- SD AUC from time zero to the last measurable plasma amiloride concentration after inhalation was 14.4 +/- 17.6 and 15.4 +/- 10.1 ng.hr/ml in the adults and adolescents.,Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[h·ng] / [ml],14.4,64648,DB00594,Amiloride
,9085317,AUC from time zero to the last measurable plasma amiloride concentration,Mean +/- SD AUC from time zero to the last measurable plasma amiloride concentration after inhalation was 14.4 +/- 17.6 and 15.4 +/- 10.1 ng.hr/ml in the adults and adolescents.,Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085317/),[h·ng] / [ml],15.4,64649,DB00594,Amiloride
,4788208,V(d),The V(d) values (350 to 380 litres) were greater than total body fluid volume suggesting extravascular sequestration of amiloride.,Kinetics and bioavailability of two formulations of amiloride in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4788208/),l,350 to 380,69775,DB00594,Amiloride
,8080005,Prenin,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [h·ml],16.6,84182,DB00594,Amiloride
,8080005,Prenin,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [h·ml],35.3,84183,DB00594,Amiloride
,8080005,Paldo,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [dl],26.1,84184,DB00594,Amiloride
,8080005,Paldo,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [dl],109,84185,DB00594,Amiloride
,12906902,flow-rate,"HPLC separation was achieved on a silica column with the mobile phase of methanol-50 mM potassium phosphate buffer (pH 3)-triethylamine (80:20:0.3, v/v), at a flow-rate of 1 ml/min.",Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906902/),[ml] / [min],1,88372,DB00594,Amiloride
,12906902,retention time,The retention time was about 5.5 min for amiloride and 12 min for mitoguazone.,Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906902/),min,5.5,88373,DB00594,Amiloride
,12906902,retention time,The retention time was about 5.5 min for amiloride and 12 min for mitoguazone.,Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906902/),min,12,88374,DB00594,Amiloride
greater,12906902,absolute recoveries,The absolute recoveries of mitoguazone and amiloride were both greater than 84%.,Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906902/),%,84,88375,DB00594,Amiloride
,1783363,rate of absorption (tmax,The rate of absorption (tmax = 3 h) and the bioavailability of the two diuretics were not significantly modified by their combination.,Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,3,95158,DB00594,Amiloride
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,2.77,95159,DB00594,Amiloride
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,2.76,95160,DB00594,Amiloride
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,15.7,95161,DB00594,Amiloride
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,14.6,95162,DB00594,Amiloride
,20146401,flow rate,The analytes were separated on a Hypersil ODS-2 column by a multiple-step linear gradient elution with a mobile phase consisting of 0.2% formic acid solution and methanol pumped at a flow rate of 1.0 mL/min.,Development and validation of a robust LC-MS-MS with atmospheric pressure chemical ionization for quantitation of carbazochrome sodium sulfonate in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20146401/),[ml] / [min],1.0,108433,DB00594,Amiloride
,2792171,apparent systemic plasma clearance,"The apparent systemic plasma clearance for both amiloride and hydrochlorothiazide was significantly reduced in the elderly when compared to the young (from 753 to 325 ml.min-1, amiloride; and from 418 to 157 ml.min-1, hydrochlorothiazide).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ml] / [min],753 to 325,138405,DB00594,Amiloride
,2792171,apparent systemic plasma clearance,"The apparent systemic plasma clearance for both amiloride and hydrochlorothiazide was significantly reduced in the elderly when compared to the young (from 753 to 325 ml.min-1, amiloride; and from 418 to 157 ml.min-1, hydrochlorothiazide).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ml] / [min],418 to 157,138406,DB00594,Amiloride
,2792171,plasma concentrations at steady state,The plasma concentrations at steady state for both drugs were greatly increased in the elderly patients (Amiloride: from 7 to 25 ng.,The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,7 to 25,138407,DB00594,Amiloride
,2792171,"Css,max","ml-1, Css,max; from 2 to 8 ng.",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,2 to 8,138408,DB00594,Amiloride
,2792171,Css,"ml-1, Css,min; and from 4 to 14 ng.",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,min,138409,DB00594,Amiloride
,2792171,Css,"ml-1, Css,min; and from 4 to 14 ng.",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,4 to 14,138410,DB00594,Amiloride
,2792171,"Css,max","ml-1, Cav; Hydrochlorothiazide: from 184 to 651 ng.ml-1, Css,max; from 31 to 121 ng.ml-1, Css,min; and from 89 to 273 ng.ml-1, Cav).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ng] / [ml],184 to 651,138411,DB00594,Amiloride
,2792171,"Css,min","ml-1, Cav; Hydrochlorothiazide: from 184 to 651 ng.ml-1, Css,max; from 31 to 121 ng.ml-1, Css,min; and from 89 to 273 ng.ml-1, Cav).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ng] / [ml],31 to 121,138412,DB00594,Amiloride
,2792171,Cav,"ml-1, Cav; Hydrochlorothiazide: from 184 to 651 ng.ml-1, Css,max; from 31 to 121 ng.ml-1, Css,min; and from 89 to 273 ng.ml-1, Cav).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ng] / [ml],89 to 273,138413,DB00594,Amiloride
,9350065,water reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[ml] / [min],23.9,139282,DB00594,Amiloride
,9350065,water reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[ml] / [min],19.8,139283,DB00594,Amiloride
,9350065,reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[μM] / [min],10.5,139284,DB00594,Amiloride
,9350065,reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[μM] / [min],18.1,139285,DB00594,Amiloride
,1320543,fractional lithium excretion,"Control levels of fractional lithium excretion (12.4 +/- 1.2%, mean +/- SEM) were not influenced by hydration, hydration plus arginine vasopressin administration or the lithium dosage.","Lithium clearance in dogs: effects of water loading, amiloride and lithium dosage. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320543/),%,12.4,143914,DB00594,Amiloride
,1320543,fractional,"The low fractional lithium excretion even during amiloride infusion (14.1-16.8%) may well be due to a high fractional reabsorption of lithium in the proximal tubules; however, a significant reabsorption of lithium distal to the proximal straight tubules by amiloride-insensitive pathways cannot be excluded.","Lithium clearance in dogs: effects of water loading, amiloride and lithium dosage. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320543/),%,14.1-16.8,143915,DB00594,Amiloride
,21491473,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 230.1 → 116.0 for amiloride, m/z 254.1 → 237.1 for internal standard, triamterine in positive mode and m/z 296.1 → 204.9 for hydrochlorothiazide, m/z 299.2 → 205.8 for internal standard, hydrochlorothiazide (13)C,d2 in negative ion mode.","A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),,296.1,145115,DB00594,Amiloride
,21491473,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 230.1 → 116.0 for amiloride, m/z 254.1 → 237.1 for internal standard, triamterine in positive mode and m/z 296.1 → 204.9 for hydrochlorothiazide, m/z 299.2 → 205.8 for internal standard, hydrochlorothiazide (13)C,d2 in negative ion mode.","A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),,299.2,145116,DB00594,Amiloride
,21491473,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 230.1 → 116.0 for amiloride, m/z 254.1 → 237.1 for internal standard, triamterine in positive mode and m/z 296.1 → 204.9 for hydrochlorothiazide, m/z 299.2 → 205.8 for internal standard, hydrochlorothiazide (13)C,d2 in negative ion mode.","A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),,205.8,145117,DB00594,Amiloride
,21491473,recovery,The mean recovery was 41.1 and 81.5% for amiloride and hydrochlorothiazide respectively.,"A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),%,41.1,145118,DB00594,Amiloride
,21491473,recovery,The mean recovery was 41.1 and 81.5% for amiloride and hydrochlorothiazide respectively.,"A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),%,81.5,145119,DB00594,Amiloride
,11861324,elimination half-life,"2. In control rats, the elimination half-life of pirfenidone following a single intravenous dose of 200 mg kg(-1) was 37 min while oral bioavailability at this dose was 25.7%.",Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),min,37,155643,DB00594,Amiloride
,11861324,oral bioavailability,"2. In control rats, the elimination half-life of pirfenidone following a single intravenous dose of 200 mg kg(-1) was 37 min while oral bioavailability at this dose was 25.7%.",Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),%,25.7,155644,DB00594,Amiloride
,11861324,EC50,5. Noradrenaline potency (positive chronotropy) was decreased in right atria (neg log EC50: control 6.92 +/- 0.06; DOCA-salt 6.64 +/- 0.08); pirfenidone but not amiloride reversed this change.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,6.92,155645,DB00594,Amiloride
,11861324,EC50,5. Noradrenaline potency (positive chronotropy) was decreased in right atria (neg log EC50: control 6.92 +/- 0.06; DOCA-salt 6.64 +/- 0.08); pirfenidone but not amiloride reversed this change.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,6.64,155646,DB00594,Amiloride
,11861324,EC50,Noradrenaline was a more potent vasoconstrictor in thoracic aortic rings (neg log EC50: control 6.91 +/- 0.10; DOCA-salt 7.90 +/- 0.07); pirfenidone treatment did not change noradrenaline potency.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,6.91,155647,DB00594,Amiloride
,11861324,EC50,Noradrenaline was a more potent vasoconstrictor in thoracic aortic rings (neg log EC50: control 6.91 +/- 0.10; DOCA-salt 7.90 +/- 0.07); pirfenidone treatment did not change noradrenaline potency.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,7.90,155648,DB00594,Amiloride
,2297454,renal clearance,"The renal clearance of amiloride was lower in the elderly than in young subjects (102 +/- 36 ml min -1 vs 300 +/- 64 ml min-1, P less than 0.001) as was the urinary excretion of amiloride (36 +/- 13 vs 62 +/- 18% of the dose, P less than 0.01).",Amiloride disposition in geriatric patients: importance of renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297454/),-1·min·ml,102,169777,DB00594,Amiloride
,2297454,renal clearance,"The renal clearance of amiloride was lower in the elderly than in young subjects (102 +/- 36 ml min -1 vs 300 +/- 64 ml min-1, P less than 0.001) as was the urinary excretion of amiloride (36 +/- 13 vs 62 +/- 18% of the dose, P less than 0.01).",Amiloride disposition in geriatric patients: importance of renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297454/),[ml] / [min],300,169778,DB00594,Amiloride
,2297454,urinary excretion,"The renal clearance of amiloride was lower in the elderly than in young subjects (102 +/- 36 ml min -1 vs 300 +/- 64 ml min-1, P less than 0.001) as was the urinary excretion of amiloride (36 +/- 13 vs 62 +/- 18% of the dose, P less than 0.01).",Amiloride disposition in geriatric patients: importance of renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297454/),%,36,169779,DB00594,Amiloride
,2297454,urinary excretion,"The renal clearance of amiloride was lower in the elderly than in young subjects (102 +/- 36 ml min -1 vs 300 +/- 64 ml min-1, P less than 0.001) as was the urinary excretion of amiloride (36 +/- 13 vs 62 +/- 18% of the dose, P less than 0.01).",Amiloride disposition in geriatric patients: importance of renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297454/),%,62,169780,DB00594,Amiloride
,10168532,effective time until return to 50% delta PD [ET50],"The duration of inhibition of PD (effective time until return to 50% delta PD [ET50] after nasal administration) was dose dependent (10(-3)M, 39 +/- 0.8 minutes; 10(-2)M; 133 +/- 14 minutes).","Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10168532/),min,39,199784,DB00594,Amiloride
,10168532,effective time until return to 50% delta PD [ET50],"The duration of inhibition of PD (effective time until return to 50% delta PD [ET50] after nasal administration) was dose dependent (10(-3)M, 39 +/- 0.8 minutes; 10(-2)M; 133 +/- 14 minutes).","Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10168532/),M,10,199785,DB00594,Amiloride
,10168532,effective time until return to 50% delta PD [ET50],"The duration of inhibition of PD (effective time until return to 50% delta PD [ET50] after nasal administration) was dose dependent (10(-3)M, 39 +/- 0.8 minutes; 10(-2)M; 133 +/- 14 minutes).","Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10168532/),min,133,199786,DB00594,Amiloride
,6736181,flow-rate,"A high-performance liquid chromatographic method has been developed for amiloride in rabbit plasma and urine which uses a reversed-phase C18 column, a mobile phase (flow-rate 2 ml/min) consisting of 32% acetonitrile in 0.15 M perchloric acid, pH 2.2, and spectrofluorometric detection via excitation at 286 nm.",High-performance liquid chromatographic analysis of amiloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736181/),[ml] / [min],2,215117,DB00594,Amiloride
,6736181,retention times,"Short retention times of about 2.3 and 3.8 min are observed for amiloride and the internal standard, triamterene, respectively.",High-performance liquid chromatographic analysis of amiloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736181/),min,2.3,215118,DB00594,Amiloride
,6736181,retention times,"Short retention times of about 2.3 and 3.8 min are observed for amiloride and the internal standard, triamterene, respectively.",High-performance liquid chromatographic analysis of amiloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736181/),min,3.8,215119,DB00594,Amiloride
,12411282,rates of mucociliary clearance,"The rates of mucociliary clearance by pretreatment with amiloride and 7% saline alone (approximately 1.4% per minute) approached the rapid mucociliary clearance rates (approximately 2.0% per minute) reported in systemic pseudohypoaldosteronism, which has loss-of-function mutations of the epithelial Na+ channel and an increased volume of airway surface liquid.",Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411282/),[%] / [min],1.4,215389,DB00594,Amiloride
,12411282,m,"The rates of mucociliary clearance by pretreatment with amiloride and 7% saline alone (approximately 1.4% per minute) approached the rapid mucociliary clearance rates (approximately 2.0% per minute) reported in systemic pseudohypoaldosteronism, which has loss-of-function mutations of the epithelial Na+ channel and an increased volume of airway surface liquid.",Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411282/),[%] / [min],2.0,215390,DB00594,Amiloride
,19346319,half-life,"[(3)H]INO-4995 was rapidly taken up by epithelial cultures and converted to the active drug, which had a half-life of 40 hours.",INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19346319/),h,40,241899,DB00594,Amiloride
,8930763,flow-rate,Reversed-phase separations were performed at ambient temperature using a non-linear gradient method with two different mobile phases: mobile phase A was 100% acetonitrile while mobile phase B was 0.15 M perchloric acid at pH 2.20 (flow-rate was 1.2 ml/min).,Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),[ml] / [min],1.2,255354,DB00594,Amiloride
,8930763,retention times,"The retention times for amiloride, benzamil (used as an internal standard), EIPA and HMA are 13.4, 19.5, 21.8 and 23.5 min, respectively.",Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),min,13.4,255355,DB00594,Amiloride
,8930763,retention times,"The retention times for amiloride, benzamil (used as an internal standard), EIPA and HMA are 13.4, 19.5, 21.8 and 23.5 min, respectively.",Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),min,19.5,255356,DB00594,Amiloride
,8930763,retention times,"The retention times for amiloride, benzamil (used as an internal standard), EIPA and HMA are 13.4, 19.5, 21.8 and 23.5 min, respectively.",Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),min,21.8,255357,DB00594,Amiloride
,8930763,retention times,"The retention times for amiloride, benzamil (used as an internal standard), EIPA and HMA are 13.4, 19.5, 21.8 and 23.5 min, respectively.",Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),min,23.5,255358,DB00594,Amiloride
,8930763,half-lives,"The half-lives of amiloride, EIPA and HMA (and their confidence intervals) in plasma after intraperitoneal injection of drugs into mice were 68.8 +/- 0.2, 31.2 +/- 2.5 and 39.3 +/- 7.9 min, respectively.",Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),min,68.8,255359,DB00594,Amiloride
,8930763,half-lives,"The half-lives of amiloride, EIPA and HMA (and their confidence intervals) in plasma after intraperitoneal injection of drugs into mice were 68.8 +/- 0.2, 31.2 +/- 2.5 and 39.3 +/- 7.9 min, respectively.",Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),min,31.2,255360,DB00594,Amiloride
,8930763,half-lives,"The half-lives of amiloride, EIPA and HMA (and their confidence intervals) in plasma after intraperitoneal injection of drugs into mice were 68.8 +/- 0.2, 31.2 +/- 2.5 and 39.3 +/- 7.9 min, respectively.",Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930763/),min,39.3,255361,DB00594,Amiloride
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),mM,2.6,255601,DB00594,Amiloride
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),mM,7.9,255602,DB00594,Amiloride
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),,520,255603,DB00594,Amiloride
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),,95,255604,DB00594,Amiloride
,8392774,Fractional potassium reabsorption,Fractional potassium reabsorption remained constant at 0.31 +/- 0.03.,Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),,0.31,255605,DB00594,Amiloride
,8392774,[K]p,"Administration of acetazolamide (100 mg kg-1 body wt) in eight dogs at [K]p 8 mM reduced fractional reabsorption of bicarbonate, chloride and sodium as much as in previous studies on normokalaemic dogs.",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),mM,8,255606,DB00594,Amiloride
,3447250,Fractional lithium excretion (FE-Li),"Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,22.6,255607,DB00594,Amiloride
greater,3447250,"fractional sodium excretion, FE-Na","Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,0.4,255608,DB00594,Amiloride
,3447250,"fractional sodium excretion, FE-Na","Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,6.9,255609,DB00594,Amiloride
less,3447250,FE-Na,"Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,0.4,255610,DB00594,Amiloride
,7943351,conductance,Hydraulic conductance of the left lung was 1.57 microliters.min-1.cmH2O-1.kg body wt-1.,Effect of lung inflation on active and passive liquid clearance from in vivo rabbit lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7943351/),[kg·μl] / [cmh2o·min],1.57,257612,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.49 × 10(-4),263590,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.80 × 10(-4),263591,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.88 × 10(-4),263592,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.064 × 10(-4),263593,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.003 × 10(-4),263594,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.090 × 10(-4),263595,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.042 × 10(-4),263596,DB00594,Amiloride
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.032 × 10(-4),263597,DB00594,Amiloride
,23224978,Km,"Jejunal uptake of cefadroxil was saturable (Km = 2-4 mM) and significantly attenuated by the sodium-proton exchange inhibitor 5-(N,N-dimethyl)amiloride.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),mM,2-4,263598,DB00594,Amiloride
,9367469,initial concentration,"The mean volume aerosolized was 3.5+/-0.3 mL during 12 min of aerosolization time; the mean initial concentration of amiloride on airway surfaces after nebulization was 1.6 x 10(-4) mol/L, with an elimination half life of approximately 23 min.",Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9367469/),[mol] / [l],1.6 x 10(-4),265496,DB00594,Amiloride
,9367469,elimination half life,"The mean volume aerosolized was 3.5+/-0.3 mL during 12 min of aerosolization time; the mean initial concentration of amiloride on airway surfaces after nebulization was 1.6 x 10(-4) mol/L, with an elimination half life of approximately 23 min.",Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9367469/),min,23,265497,DB00594,Amiloride
,9367469,Peak plasma concentrations,"Peak plasma concentrations of amiloride (30 min, 3.36+/-0.70 ng/mL) suggest early absorption across lung surfaces, rather than via the GI route.",Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9367469/),[ng] / [ml],3.36,265498,DB00594,Amiloride
,9367469,urinary excretion,"Mean urinary excretion of amiloride over 72 h was 0.63+/-0.07 mg, with 87% excreted in the first 24 h.",Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9367469/),mg,0.63,265499,DB00594,Amiloride
